Medlab 2021 Australian Pain Society 41st Annual Scientific Meeting

2021 Australian Pain Society 41st Annual Scientific Meeting

Date of Event:   2021-04-19 - 2021-04-20
Location:  Virtual

Medlab is proud to present at the 2021 Australian Pain Society 41st Annual Scientific Meeting, on the 19th of April.

 

SPONSORED SESSION

Preliminary analgesic evidence of cannabinoids delivered via NanoCelle® (submicron particle technology) and its further research addressing gaps in cannabis dosing efficacy.

Results of a completed clinical study at RNSH investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers. Medlab’s water-soluble nanoparticle delivered cannabis-based medicine showed superior bioavailability and tolerability compared to ethanol-based delivery of cannabis-based medicines across the oro-buccal mucous membrane. The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis. 

  • Results published in the Asia Pacific Journal of Clinical Oncology. #219 https://onlinelibrary.wiley.com/doi/10.1111/ajco.13498 
  • Preparations to run phase III trial AU, UK and US

Presenting an update on current research is important for those physicians who are currently prescribing medicinal cannabis for the patients where traditional therapies have failed. The level of current evidence on medicinal cannabis efficacy is low to moderate, and further research is needed for the safety of patients.

Location - Virtual
Time - 8:00am - 9:00am
Dates - 19 April 2021

SPEAKER

Dr. Jeremy Henson, Medical Affairs Director of Medlab
Medical Affairs Director
Dr. Jeremy Henson

Jeremy has 18 years’ experience in cancer research. He is the Principal Investigator of the Cancer Cell Immortality research group, UNSW Medicine, where his research involves the development of cancer treatments and diagnostics that target telomere maintenance mechanisms (telomerase and ALT). Jeremy discovered and patented the C-Circle biomarker and assay for the alternative-lengthening-of-telomeres (ALT) cancer mechanism (Nature Biotechnology, 2009) and is currently developing the C-Circle Assay as a cancer diagnostic and using it to perform a high-throughput screen for ALT inhibitors, which could be used as ALT-targeted cancer therapies. 

Jeremy is also Chief Career Medical officer at Lakeview Private Hospital, where he is a member of the Medical Advisory and Root Cause Analysis Committees, and a clinical tutor at Prince of Wales Clinical School, UNSW Faculty of Medicine. At Medlab, Jeremy's responsibilities include overseeing pharmacovigilance, research, clinical trials and new product development.

COMMENTS 0

Tell us what you think login to share your thoughts.